ArticleBritish journal of haematology2025
Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.Blood advances · 2026Article
- From production to bedside: A tiered QC framework for regulatory alignment and analytical comparability in decentralized CGT.Regenerative therapy · 2026Review
- Current treatment algorithm: diffuse large B cell lymphoma.Blood cancer journal · 2026Review
- Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma.British journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is effective for relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). However, delays between apheresis and infusion frequently occur due to limited facility capacity and prolonged bridging therapy, and the clinical impact of such delays remains uncertain. We retrospectively analysed R/R DLBCL patients who underwent CAR-T-cell therapy at Kyoto University Hospital. Among 90 patients, the median apheresis to infusion interval was 66 days (range, 28-203). Patients were categorized into delayed (≥66 days) and non-delayed (<66 days) groups. Baseline characteristics at infusion were similar, whereas adverse features such as extranodal involvement and stable/progressive disease (SD/PD) were less common in the delayed group. Multivariate analysis identified delayed infusion as a significant negative prognostic factor for progression-free survival (adjusted hazard ratio [aHR] 3.13; 95% confidence interval [CI] 1.63-6.00; p = 0.001), along with extranodal involvement (aHR 2.39; p = 0.004), SD/PD (aHR 2.66; p = 0.005), bulky disease (aHR 3.08; p = 0.008) and treatment with tisa-cel (aHR 5.26; p = 0.001). Overall survival was also inferior in the delayed group (aHR 2.53, 95% CI 1.29-4.96; p = 0.007). Minimizing apheresis to infusion interval through improved workflows, institutional capacity and avoiding prolonged bridging in non-responders may enhance outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.